Home

Insulin glargine 300 units/ml

Insulin glargine 300 units/mL for the treatment of

  1. e Hagedorn insulin), with or without oral antihyperglycaemic drugs (excluding sulphonylureas and.
  2. Insulin glargine is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. It acts longer than regular insulin, providing a low, steady level of insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy
  3. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2) Gla-300 was as effective as Gla-100 and associated with a lower risk of hypoglycemia during the night and at any time of the day
  4. Objective: To compare efficacy and safety of insulin glargine 300 units/mL (Gla-300) and 100 units/mL (Gla-100) in children and adolescents (6-17 years old) with type 1 diabetes. Research design and methods: EDITION JUNIOR was a noninferiority, international, open-label, two-arm, parallel-group, phase 3b trial. Participants were randomized 1:1 to Gla-300 or Gla-100, titrated to achieve fasting self-monitored plasma glucose levels of 90-130 mg/dL (5.0-7.2 mmol/L), with continuation of prior.
  5. a pharmacokinetic (pk)/pharmacodynamic (pd) euglycemic clamp study at steady state in people with type 1 diabetes showed that the basal insulin analog insulin glargine 300 units/ml (gla-300) provides more consistent and prolonged insulin exposure compared with insulin glargine 100 units/ml (gla-100), resulting in blood glucose control that lasts
  6. Toujeo (insulin glargine injection) 300 Units/mL is a long-acting insulin injection which helps manage A1C and control blood sugar in adults and children who are 6 years of age and older with diabetes mellitus. Learn more

Insulin glargine 300 units/mL (Gla-300) is a second-generation basal insulin analog with improved pharmacokinetic and pharmacodynamic properties compared with Gla-100 ( 13, 14 ) Insulin glargine 300 units/mL (U-300): -Initial dose: Approximately one-third to one-half total daily insulin requirement subcutaneously once a day; maximum glucose lowering effect may take 5 days to fully manifest and the first dose may be insufficient to cover metabolic needs during the first 24 hour; monitor closel What is Toujeo ® (insulin glargine injection) 300 Units/mL? Prescription Toujeo is a long-acting man-made insulin used to control high blood sugar in adults and children who are 6 years of age and older with diabetes mellitus. Toujeo is not for use to treat diabetic ketoacidosi Objective: To compare insulin glargine 300 units/mL (Gla-300) versus insulin degludec 100 units/mL (IDeg-100) in this first head-to-head randomized controlled trial. Research design and methods: BRIGHT ( NCT02738151 ) was a multicenter, open-label, active-controlled, two-arm, parallel-group, 24-week, noninferiority study in insulin-naive patients with uncontrolled type 2 diabetes

Insulin Glargine 300 Units/Ml Pen - Injectio

  1. Insulin Glargine 300 U/mL Monograph August 2015 Updated version may be found at www.pbm.va.gov or PBM INTRAnet 3 Study drug was adjusted once weekly to a pre-breakfast SMBG goal of 80-100mg/dl based on the median of the previous 3 days. Adjustments for both groups were restricted to changes divisible by 3 units, the smalles
  2. Each ml contains 300 units insulin glargine* (equivalent to 10.91 mg). SoloStar pen Each pen contains 1.5 ml of solution for injection, equivalent to 450 units. DoubleStar pen Each pen contains 3 ml of solution for injection, equivalent to 900 units. * Insulin glargine is produced by recombinant DNA technology in Escherichia coli
  3. The new insulin glargine 300 units/mL (Gla-300) has a reduced redissolution rate following subcutaneous injection as compared with Gla-100 and thereby the potential for meeting this need ( 12, 13 ). Glucose clamp studies confirm that Gla-300 provides flatter and more prolonged pharmacokinetic and pharmacodynamic profiles than Gla-100 ( 12, 13 )
  4. Insulin Glargine | Toujeo® (insulin glargine injection) 300 Units/mL HCP Site For higher-dose patients, choose Toujeo ® Max SoloStar ® The highest capacity basal insulin pen on the market 1-6 Learn more Toujeo Max SoloStar is recommended for appropriate patients who require at least 20 units of basal insulin per day. Dosing Calculato
  5. Toujeo contains the same active ingredient, insulin glargine, as Lantus ®. The concentration of insulin glargine in Toujeo is 300 units per mL. Insulin pens and needles must never be shared between patients. Do NOT reuse needles. Monitor blood glucose in all patients treated with insulin

Insulin glargine 300 IU/mL solution (Gla-300) is a basal insulin, administered subcutaneously once daily. It is approved only for use in patients aged ≥ 18 years. Similar efficacy and safety to that of insulin glargine 100 IU/mL solution (Gla-100) Gla-300 is a concentrated formulation of the already PBS-listed Gla-100 To address this problem, a new insulin glargine (Gla-300), which contains 300 units/mL insulin glargine, has been developed. After subcutaneous injection, Gla-300 has been shown to have smoother, more stable, and prolonged pharmacokinetic and pharmacodynamic profiles than Gla-100, resulting from an extended release of glargine from the subcutaneous depot ( 9 ) Insulin Glargine is a long-acting basal insulin used to treat diabetes patients. It is available in three concentrations i.e. U-100 (Lantus), U-300 (Toujeo), and U-500 (Toujeo Max). U-100 means 100 units per ml; U-300 means 300 units per ml; and U-500 means 500 units per ml. This means that U-100 is 3 & 5 times less concentrated than U-300 & U-500

In Brief New insulin glargine 300 units/mL (Gla-300) is a formulation of insulin glargine that has a more constant pharmacokinetic profile with a prolonged duration of action. The EDITION clinical trial program showed that the use of Gla-300 leads to glycemic control comparable to that of insulin glargine 100 units/mL in a wide range of populations of people with diabetes The mean daily insulin dose (± SD) on day 1 was 16.9 ± 4.4 units (0.19 ± 0.04 units/kg) for Gla-300 and 10.2 ± 1.9 units (0.12 ± 0.04 units/kg) for IDeg-100. At week 24, the mean daily dose was 50.5 ± 25.6 units (0.54 ± 0.26 units/kg) for Gla-300 and 39.2 ± 23.3 units (0.43 ± 0.24 units/kg) for IDeg-100 ( Supplementary Fig. 2A ) Materials and methods: BRIGHT was a multicentre, open-label, randomized, active-controlled, two-arm, parallel-group, 24-week study in insulin-naïve patients with uncontrolled type 2 diabetes initiated on glargine 300 U/mL (Gla-300) (N = 466) or degludec (IDeg-100) (N = 463). Predefined efficacy and safety outcomes were investigated during the initial 12-week titration period Easy-to-read patient leaflet for Insulin Glargine (U-300) Pens. Includes indications, proper use, special instructions, precautions, and possible side effects

What is Toujeo®(insulin glargine injection) 300 Units/mL? Prescription Toujeo is a long-acting man-made insulin used to control high blood sugar in adults and children who are 6 years of age and older with diabetes mellitus. Toujeo is not for use to treat diabetic ketoacidosi The 300 units/mL (U-300) is highlighted in honey gold on the labels of TOUJEO and TOUJEO Max SoloStar single-patient-use prefilled pens.Inform patients that TOUJEO (insulin glargine injection) 300 units/mL contains 3 times as much insulin in 1 mL as standard insulin (100 units/mL) Unit NHS indicative price Drug tariff Drug tariff price; Insulin glargine 300 unit per 1 ml; 3: pre-filled disposable injection (POM) £32.14 Part VIIIA Category C: £32.1 ANNOUNCER: These instructions do not replace the guidance of your doctor or the instructions for use that accompanies the Toujeo (insulin glargine injection) 300 Units/mL SoloStar or Toujeo Max SoloStar pens.People who have vision problems should not use the Toujeo SoloStar or Toujeo Max SoloStar pen without help from a person trained to use the respective pens

U-300 (300 units/mL) insulin glargine is a long-acting basal insulin with low within-day variability, high day-to-day reproducibility, longer duration, and constant pharmacokinetic profile compared with U-100 (100 units/mL) insulin glargine. U-300 was evaluated in six randomized, active-comparator, open-label, Phase III clinical studies. Introduction: To evaluate the clinical effectiveness of Gla-300 units/mL (Gla-300) in the treatment of patients with type 2 diabetes (T2DM) uncontrolled by basal insulin in real-life clinical settings in the Czech Republic (TOPAZ study). Methods: TOPAZ was a prospective, multi-center, non-interventional, 6-month study. Of the 312 patients screened, 289 were evaluated at month 6

Toujeo (insulin glargine 300 units/mL) DoubleStar – New

New insulin glargine 300 units/mL versus glargine 100

  1. Insulin glargine 300 units/mL: Insulin glargine 300 units/mL (Gla-300) is a formulation of insulin glargine that delivers the same number of insulin units in one-third of the injectable volume of insulin glargine 100 units/mL (Gla-100). Glucose control: Recently approved in the United States and in Europe for use in type 1 and type 2 diabetes.
  2. Purpose The pharmacokinetics, efficacy, and safety of U-300 insulin glargine for the management of diabetes are reviewed. Summary U-300 (300 units/mL) insulin glargine is a long-acting basal insulin with low within-day variability, high day-to-day reproducibility, longer duration, and constant pharmacokinetic profile compared with U-100 (100 units/mL) insulin glargine
  3. To compare the second‐generation basal insulin glargine 300 units/mL (Gla‐300) and first‐generation basal insulins on glycaemic control and hypoglycaemia risk in older adults with type 2 diabetes (T2D). Materials and methods. DELIVER 3 was a retrospective observational cohort study of electronic medical records
  4. New insulin glargine 300 units/mL (Gla-300) is a basal insulin that provides the same number of units as Gla-100 in a third of the volume. Compared with Gla-100, Gla-300 has shown more constant and prolonged pharmacokinetic (PK)/pharmacodynamic (PD) profiles. Gla-300 has been shown to achieve similar glycemic control with less nocturnal hypoglycemia compared with Gla-100, and lower hypoglycemia..

Insulin glargine 300 U/mL (IGla300) is a recombinant‐human insulin analog in which 2 arginine residues are added to position B30. 3 This allows glargine to remain in solution at a pH of 4.0 (as supplied) and form stable hexamers in neutral pH when injected into the subcutaneous space U100 stands for: 100 Units of insulin per 1mL (milliliter) U500 stands for: 500 Units of insulin per 1mL (milliliter) So, if you have a U100 insulin product, and you need to inject 50 units, that would come out to 0.5 mL. Similarly, if you have a U500 insulin product, and you need to inject 50 units, that would come out to 0.1 mL

Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla

Glargine-300 is a new long-acting insulin analog, recently approved by both the US Food and Drug Administration and European Medicines Evaluation Agency for marketing in the US and Europe, respectively. Glargine-300 is a three times more concentrated formulation of traditional glargine, ie, 300 units/mL versus 100 units/mL New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care 2015. 7. Rosselli JL, et al. U300 insulin glargine: a novel basal insulin for type 1 and type 2 diabetes Presentation: Each ml contains 100 units insulin glargine* (equivalent to 3.64 mg). Each pen contains 3 ml of solution for injection, equivalent to 300 units. Dosage and administration: Semglee ® (insulin glargine) has a prolonged duration of action. It should be administered once daily at any time but at the same time each day

Comparison of Insulin Glargine 300 Units/mL and 100 Units

High Strength Insulins: Humalog® 200 (insulin lispro 200 units/ml), Toujeo® (Insulin glargine 300 units/ml) and Tresiba® (insulin degludec 200 units/ml) have been added to the Bucks Formulary. All high strength insulins are Amber Recommended . Restricted - initiation on the recommendation of Consultant Diabetologist or Diabetes Specialist. Riddle MC, Bolli GB, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37(10):2755-2762. 35. Terauchi Y, Koyama M, Cheng X, et al Each ml contains 100 units insulin glargine* (equivalent to 3.64 mg). Each pen contains 3 ml of solution for injection, equivalent to 300 units. Dosage and administration: Semglee® (insulin glargine) has a prolonged duration of action. It should be administered once daily at any time but at the same time each day

Long Acting Insulin Toujeo® (insulin glargine injection

Insulin Dosage Calculator For T2DM | Toujeo® (insulinEMA: Approved on the market since June 2000, Insulin

Toujeo contains the same active ingredient, insulin glargine, as Lantus ®. The concentration of insulin glargine in Toujeo is 300 units per mL. Insulin pens and needles must never be shared between patients. Do NOT reuse needles. Monitor blood glucose in all patients treated with insulin. Modify insulin regimens only under medical supervision - transferring to Tresiba from insulin glargine (300 units/mL) Patients with type 1 diabetes mellitus For patients with type 1 diabetes a dose reduction of 20% based on the previous basal insulin dose or basal component of a continuous subcutaneous insulin infusion regimen should be considered with subsequent individual dosage adjustments based. Yki-Jarvinen H, Bergenstal R, Zieman M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014;37:3235-43

Insulin glargine 300 units/mL (Gla-300) is a three-fold con-centrated formulation of insulin glargine 100 units/mL (Gla-100) that can be calibrated in 1-unit increments up to 80 units per injection [1]. In euglycemic clamp studies, Gla-300 provid - Original Article Drug/Regime Toujeo (insulin glargine 300 units/ml) is the third insulin to be approved in Europe at a higher strength than the European Union‑wide standard of 100 units/ml. Insulin degludec and insulin lispro are already available at a 200 units/ml strength

Insuline Glargine Toujeo Solar Star Pre Filled Disposable

SAIE.DIA.19.07.0155b - July 2019 What is Toujeo®? Toujeo® is a pre-filled injection pen which contains insulin glargine 300 units per ml. It is a modified insulin, very similar to human insulin. Toujeo® lowers your blood sugar steadily over a long period of time. It is used for once daily dosing Insulin glargine 300 U/mL (Gla-300) is a new generation basal insulin product that has been demonstrated to have more stable pharmacokinetic and pharmacodynamic characteristics than insulin glargine 100 U/mL (Gla-100). To evaluate the real-world benefits of Gla-300 in reducing nocturnal fluctuations in blood glucose levels and nocturnal hypoglycemia, 10 Taiwanese patients using Gla-100 for. Insulin Glargine 300 Units / ml 1.5 ml 1 pc REMINDER: A doctor's prescription is required to purchase this product. Please upload your prescription by clicking the link above.Our pharmacist will also get in touch with you to validate your prescription Insulin Glargine (rx) Dosage Forms & Strengths injectable solution 100 units/mL (Lantus; 10mL vial) 100 units/mL (Lantus SoloSTAR; Basaglar KwikPen; 3 mL disposable prefilled pens) 300 units/mL (Toujeo; 1.5 mL SolosStar disposable prefilled pen) Note: Recent studies have suggested that glargine-300 extends blood glucose control well beyond 24 hr Type 1 or 2 Diabetes Mellitus Lantus and Toujeo.

Insulin Glargine Dosage Guide + Max Dose, Adjustments

Insulin glargine is a long-acting, or basal insulin that is generally dosed once daily (although Lantus can be dosed twice daily for some individuals). The main difference between Toujeo and Lantus is that Toujeo is three times as concentrated: Lantus contains insulin glargine 100 units/mL. Toujeo contains insulin glargine 300 units/mL TOUJEO is supplied as a sterile solution containing 300 Units/mL of insulin glargine for subcutaneous injection. Insulin glargine differs from natural human insulin in that the amino acid asparagine at position 21 of the A-chain is replaced by glycine and two arginines remain at the C-terminus of the B Injection: 300 units per mL of insulin glargine available as a clear, colorless, solution in: 1.5 mL TOUJEO SoloStar single-patient-use prefilled pen (450 units/1.5 mL). 3 mL TOUJEO Max SoloStar single-patient-use prefilled pen (900 units/3 mL). 4 CONTRAINDICATIONS TOUJEO is contraindicated

Long Acting Insulin For Diabetes Lantus® (insulin

Lantus® (insulin glargine, 100 units/mL) solution for injection has been available since 2000, and until recently was the only insulin glargine product in the UK. In August 2015, Sanofi-Aventis launched Toujeo®, a concentrated insulin glargine product of strength 300 units/mL Insulin Injection White Pen With Yellow Liquid Dispensing Syringe Quick Detail: Delfu prefilled plastic insulin pen used for prefilled 3ml cartridge applied low cost medical injections. Offers consistent, accurate and convenient dosage delivery, preferred by diabetes patients for frequent and precise insulin injections. Video abstract: View a video abstract for this article. Aims This multicentre (N = 104), randomized controlled phase 4 study compared the efficacy and safety of insulin glargine 300 units/mL (Gla‐.. 300 units/ml to Lantus Lantus and Toujeo (insulin glargine 300 units/ml) are not bioequivalent and are not directly interchangeable. To reduce the risk of hypoglycemia, patients who are changing their basal insulin regimen from an insulin regimen with once daily insulin glargine 300 units/ml to a once daily regime

More Similarities Than Differences Testing Insulin

insulin preparations in a concentration higher than 100 units/mL. These might be particularly useful in people with significant insulin resistance and high insulin requirement. U-200 insulin has low variability and lower (nocturnal) or similar risk of hypoglycaemia compared with U-100 insulin but is currently more expensive. U-300 glargine. 0.1 ml. U-100 10 units. U-200 20 units. U-300 30 units. U-500 50 units. This means you use less volume for the same number of units. 50 units. U-100 0.5 ml. U-200 0.25 ml. U-300 0.167 ml. U-500 0.1 ml. Remember: Insulin is dosed in units. If a different concentration is used, the units will remain the same but the volume will change. 2.4 Changing to REZVOGLAR from Other Insulin Therapies • If changing patients from once-daily insulin glargine, 300 units/mL, to once-daily REZVOGLAR, the recommended initial REZVOGLAR dose is 80% of the insulin glargine, 300 units/mL dose that is being discontinued. This dose reduction will lower the likelihood of hypoglycemi

Insulin Glargine Rdna Origin Injectio 300 Units/3 mLToujeo Insulin Glargine Injection, Box, Treatment

• For twice daily insulin or insulin glargine (300 Units/mL), the total daily dose previously used should be reduced by 20% to choose the SULIQUATM starting dose. • For any other basal insulin, the same rule as for insulin glargine (100 Units/mL) should be applied Introduction Older age and longer disease duration are key risk factors for hypoglycemia in patients with type 2 diabetes (T2D) who receive insulin. Previous studies have shown that insulin glargine 300 U/mL (Gla-300) improves glycemic control and reduces the risk of hypoglycemia, but whether this effect is observed in older patients switching from neutral protamine Hagedorn (NPH) insulin is. To compare the efficacy and safety of new insulin glargine 300 units/mL (Gla-300) with glargine 100 units/mL (Gla-100) in people with type 2 diabetes on basal insulin (≥42 units/day) plus mealtime insulin. RESEARCH DESIGN AND METHODS. EDITION 1 (NCT01499082) was a 6-month, multinational, open-label, parallel-group study

Toujeo 300 units/ml DoubleStar, solution for injection in

  1. Endulin Select™ 100 units/ml solution for injection in pre-filled pen cartridge 2. Qualitative and quantitative composition Each ml contains: 100 units (equivalent to 3.64 mg) Insulin glargine produced by recombinant DNA technology in Pichia pastoris. Each pen contains 3 ml of solution for injection, equivalent to 300 units
  2. glargine 300 Units/mL to once daily Lantus, the recommended initial Lantus dose is approximately 80% of the insulin glargine 300 Units/mL that is being discontinued. In clinical studies, when adult patients were transferred from once daily NPH human insulin o
  3. It was uncertain whether an algorithm that involves increasing insulin dosages by 1 unit/day may cause more hypoglycemia with the longer-acting insul
  4. Pharmacological action: Contains insulin glargine Presentation1: Each ml contains 300 units insulin glargine* (equivalent to 10.91 mg). Each pen (Toujeo® SoloStar® pre-filled pen) contains 1.5 ml of solution for injection, equivalent to 450 units. *Insulin glargine is produced by recombinant DNA technology in Escherichia coli1

Video: New Insulin Glargine 300 Units/mL Versus Glargine 100

Insulin Glargine Toujeo® (insulin glargine injection

Each ml of the solution contains 300 units of insulin glargine (equivalent to 10.91 mg). Each pen contains 1.5 ml of solution for injection, equivalent to 450 units. The other ingredients are: zinc chloride, metacresol, glycerol, water for injections, and sodium hydroxide (see section 2 Important information about some of the ingredients of. For patients controlled on Lantus or Semglee (insulin glargine, 100 units/mL) expect that a higher daily dose of Toujeo will be needed to maintain the same level of glycemic control Switching from intermediate-to-long-acting insulins to insulin glargine 100 units/mL Injection: 300 units per mL of insulin glargine available as a clear, colorless, solution in: • 1.5 mL TOUJEO SoloStar disposable prefilled pen (450 units/1.5 mL). • 3 mL TOUJEO Max SoloStar disposable prefilled pen (900 units/3 mL) Indications and Usage for Toujeo® (insulin glargine injection) 300 Units/mL Toujeo is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients 6 years and older with diabetes mellitus. Limitations of Use: Toujeo is not recommended for treating diabetic ketoacidosis. Important Safety Informatio

Insulin glargine 300 units/ml (Toujeo) is a basal insulin for once‑daily administration at any time of the day, preferably at the same time every day. When needed, people can administer Toujeo up to 3 hours before or after their usual time of administration FDA Approves New Maximum-Unit Insulin Pen. The Max SoloStar from Sanofi is capable of carrying 300 units/mL of insulin glargine, and administer 160 units/mL in a single injection. The US Food and Drug Administration (FDA) has approved glargine 300 units/mL insulin pen (Toujeo Max SoloStar) as the newest device for insulin injection therapy Insulin glargine 300 units/mL (Gla-300), with a flatter pharmacodynamic profile compared with insulin glargine 100 units/mL (Gla-100), is an approach to this problem Insulin glargine 300 units/ml Six simple steps for injecting 1 0 0 1 5 0 2 0 300 units/ml injection insulin glARGine Lot : EXP : 450 units/1.5 ml MAT <123456> Always use a new needle Never extract with a syringe SC--0 1 50 1 0 1 5 0 2 0 0 units/ml 300 injection insulin glARGine Lot : EXP : MAT <123456>

® 300 units/ml(in the SoloStar® or DoubleStar® insulin pen devices) may be considered in people with type 2 diabetes mellitus prescribed a long acting insulin analogue (insulin glargine or insulin detemir 100units/ml) who meet the following criteria Toujeo is a sterile solution containing 300 units of insulin glargine per mL. Sanofi-aventis also owns and markets Lantus, a sterile solution containing 100 units of insulin glargine per mL (NDA# 21081). The applicant is seeking to indicate Toujeo to improve glycemic control in adults with diabetes mellitus Each ml contains 100 units insulin glargine* (equivalent to 3.64 mg). Each pen contains 3 ml of solution for injection, equivalent to 300 units. *Insulin glargine is produced by recombinant DNA technology in Pichia pastoris. For the full list of excipients, see section 6.1 Toujeo (insulin glargine) 300 units per mL Tresiba (insulin degludec) 100 units per mL 200 units per mL Levemir (insulin detemir) 100 units per mL Does Long-acting insulin Come in a Pen or in Vials? Depending on the product, long-acting insulin may be available in a prefilled pen, a vial, or both. Prefilled pens usually require only an insulin. Sanofi insulins included in this program are: ADMELOG (insulin lispro injection) 100 Units/mL, TOUJEO ® (insulin glargine injection) 300 Units/mL, LANTUS ® (insulin glargine injection) 100 Units/mL and APIDRA ® (insulin glulisine injection) 100 units/mL. The Insulins Valyou Savings Program applies to the cost of medication. There are other relevant costs associated with overall treatment

Rotating from an injection site where lipodystrophy/cutaneous amyloidosis is present to an unaffected site may increase risk of hypoglycemia. Do not dilute or mix insulin glargine with any other insulin formulation or solution. Insulin glargine prefilled pens are available in concentrations of 100 units/mL and 300 units/mL New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014;37(12):3235-3243. 43. Badik J, Chen J, Letvak K, SoTY. Hypersensitivity reaction to insulin glargine and. Aims. To compare 12-month clinical effectiveness of insulin glargine 300 units/mL (Gla-300) versus first-generation basal insulin analogues (BIAs) (insulin glargine 100 units/mL [Gla-100] or insulin detemir [IDet]) in patients with type 2 diabetes (T2D) who were at high risk of hypoglycaemia and switched from one BIA to a different one (Gla-300 or Gla-100/IDet) in a real-world setting insulin glargine 300 units/mL Property of the Sanofi group toujeo-ccdsv1-piv1-30jun15 Page 4 . therapy, including iinsulin glargine 100 units/mn L therapy, are considerably lower than the pharmacological concentrations required to activate the IGF 1 pathway (insulin Glargine Injection) 300 Units/ml. Toujeo® is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. Limitations of Use: Toujeo® is not recommended for treating diabetic ketoacidosis. Contraindications Toujeo® is contraindicated during episodes of hypoglycemia and in patients. Summary: U-300 (300 units/mL) insulin glargine is a long-acting basal insulin with low within-day variability, high day-to-day reproducibility, longer duration, and constant pharmacokinetic.